Abstract

Muskan Patel*, Kunjal Kadiya, Dhwanit Darji, Kuldeep Choubisa

ABSTRACT

Schizophrenia is a chronic, debilitating neurological condition that has a significant public health burden worldwide. Dopamine D2 receptor antagonists and partial agonists have long been considered effective in reducing positive symptoms and therefore are well known to treat negative symptoms, but they can hardly cope with negative and cognitive symptoms in addition to their large metabolic and neurological side effects. Cobenfy is a fixed-dose combination of xanomeline and trospium which is the first clinically approved non-dopaminergic antipsychotic. The combination of these two modulation for the M1/M4 receptor provides cholinergic equilibrium in key brain regions involved in psychosis. This review explores Cobenfy’s mechanism of psychotherapy, clinical development, efficacy, safety and implications for reorienting schizophrenia management. Early-phase and pivotal Phase III studies show that Cobenfy does indeed improve clinically meaningful symptoms with rapid onset of action, a good safety profile and minimal risk for metabolic and extrapyramidal side effects. Cobenfy might be an indication of a shift from dopaminergic antagonism towards a more nuanced neurochemical modulation in the treatment of psychotic disorders.